Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Firibastat

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 18, 2021

            Details:

            Phase III Pivotal REFRESH Study is part of firibastat’s Phase III clinical development and aims to assess long-term safety as well as the three-month efficacy after a single daily dose of firibastat 1000mg in treatment resistant hypertensive patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Firibastat

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Faran Shimi Pharmaceutical Company

            Deal Size: Undisclosed Upfront Cash: $12.1 million

            Deal Type: Collaboration December 15, 2020

            Details:

            Under the terms of the agreement, Faran will receive the exclusive rights to market Firibastat for the treatment of difficult-to-treat / resistant hypertension in Greece.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Firibastat

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Xediton Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: $11.3 million

            Deal Type: Licensing Agreement October 28, 2020

            Details:

            Under the terms of the agreement, Xediton Pharmaceuticals will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat/resistant hypertension in Canada.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Firibastat

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Qilu Pharmaceutical Co., Ltd.

            Deal Size: Undisclosed Upfront Cash: $50.0 million

            Deal Type: Licensing Agreement October 19, 2020

            Details:

            Under the terms of the agreement, Qilu Pharmaceutical will receive the exclusive rights to market firibastat for the treatment of difficult-to-treat / resistant hypertension in China, including Hong Kong and Macau.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Firibastat

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 13, 2020

            Details:

            First patient in the Company’s FRESH study (Firibastat in treatment-RESistant Hypertension) in difficult-to-treat(1) or resistant(2) hypertension. The study is being conducted jointly with its partner in Latin America, the Biolab Sanus Pharmaceutical laboratory.